Jove
Visualize
联系我们

相关概念视频

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

323
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
323
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

335
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
335
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

256
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
256
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

284
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

279
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
279
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.3K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Culmerciclib: First Approval.

Drugs·2026
Same author

Plozasiran: First Approval.

Drugs·2026
Same author

Donidalorsen: First Approval.

Drugs·2025
Same author

Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults.

CNS drugs·2025
Same author

Lisaftoclax: First Approval.

Drugs·2025
Same author

Clesrovimab: First Approval.

Drugs·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Feb 17, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

普佐尔卡巴塔基因自细胞:儿童首次获得批准

Yahiya Y Syed1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com.

Paediatric drugs
|February 16, 2026
PubMed
概括
此摘要是机器生成的。

一种新的CAR T细胞疗法Puzolcabtagene autoleucel已在中国获得批准,用于治疗年轻患者复发或耐药B细胞急性淋巴细胞白血病. 这种疗法向CD19阳性细胞,以加强癌症治疗.

更多相关视频

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

19.0K
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

574

相关实验视频

Last Updated: Feb 17, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
09:29

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

19.0K
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)
06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

574

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 细胞疗法细胞疗法

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法代表了个性化癌症治疗的重大进展.
  • 卡尔T细胞疗法涉及基因工程患者的T细胞以准和摧毁癌细胞,如B细胞恶性瘤.
  • Puzolcabtagene autoleucel是针对B细胞急性淋巴细胞白血病 (B-ALL) 和其他B细胞淋巴瘤开发的创新型自主CAR T细胞疗法.

研究的目的:

  • 总结一下Puzolcabtagene Autoleucel的发展里程碑.
  • 为了突出中国第一个监管批准的puzolcabtagene autoleucel.
  • 为提供对这种新的CAR T细胞治疗B细胞恶性瘤的概述.

主要方法:

  • 开发一种自身的,人性化的抗CD19CART细胞产品.
  • 工程T细胞表达一种向CD19抗原的CAR,结合人性化的单链变量片段以最大限度地降低免疫性.
  • 对CD19阳性复发性或耐火性B细胞急性淋巴细胞白血病的治疗进行临床评估.

主要成果:

  • 普佐尔卡巴泰基因 (Puzolcabtagene autoleucel) 于2025年11月4日在中国获得了首次监管批准.
  • 该批准用于治疗3至21岁的患有CD19阳性复发性或耐火性B细胞急性淋巴细胞白血病 (R/R B-ALL) 的患者.
  • 该疗法利用直接细胞毒性,亡诱导和TNF连接体介导的途径来消除癌细胞.

结论:

  • 在中国,Puzolcabtagene autoleucel标志着R/R B-ALL在特定的儿科和年轻成年人群中具有重要的治疗选择.
  • zolcabtagene autoleucel的开发强调了血液恶性瘤的CAR T细胞疗法的进展.
  • 这项批准标志着个性化免疫疗法用于B细胞癌症的临床转化中的一个关键里程碑.